Patients randomized to receive risankizumab 150 mg over 52 weeks of treatment achieved ≥ 20% improvement in American College of Rheumatology criteria (ACR20) at week 52 across several subgroups, including demographics, disease characteristic, and prior treatment history, Joseph F Merola, MD, MMSc, reported during his poster presentation at ACR Convergence 2022 on November 12, 2022.

Dr Merola is an associate professor at Harvard Medical School and Brigham and Women's Hospital in Boston, Massachusetts.

In this post hoc, integrated analysis of the KEEPsAKE 1and KEEPsAKE 2 randomized clinical trials of risankizumab, efficacy was defined as achievement of ACR20 at week 52. Among 1408 patients initially randomized to receive either risankizumab 150 mg or placebo, 1354 continued into the open-label periods; 1235 patients were still participating in the trial at the time of data cutoff.

“In the analysis, a generally consistent proportion of patients initially randomized to receive continuous RZB achieved ACR20 at week 52, regardless of age, sex, race, body mass index, PsA duration, baseline high-sensitivity C-reactive protein levels, concomitant use of csDMARDs [conventional synthetic disease-modifying antirheumatic drugs] at baseline, or prior use of biologic therapy,” Dr Merola explained. In addition, patients who were switched from placebo to risankizumab also achieved similar ACR20 response rates at week 52 with comparable consistent efficacy across subgroups.

“These efficacy results support long-term use of risankizumab in patients across multiple patient and psoriatic disease characteristics,” Dr Merola stated.

—Rebecca Mashaw

Reference:

Merola J, Callis-Duffin K, Padilla B, et al. 0308. Risankizumab (RZB) demonstrates long-term efficacy across subgroups in patients with active psoriatic arthritis (PsA): A post hoc, integrated analysis from the phase 3 (KEEPsAKE 1 and KEEPsAKE 2) studies. Presented at: American College of Rheumatology Convergence. November 12, 2022. Philadelphia, Pennsylvania.